ipragliflozin + miglitol

**ipragliflozin + miglitol** is a combination of two oral antidiabetic agents used for glycemic control in type 2 diabetes. **Ipragliflozin (ASP1941)** is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion through inhibition of renal glucose reabsorption[5][7][9]. **Miglitol** is an alpha-glucosidase inhibitor that delays intestinal carbohydrate digestion, leading to reduced postprandial glucose absorption and lower post-meal glucose spikes[2][4][6][8]. The combination targets complementary mechanisms—renal glucose excretion and delayed intestinal glucose absorption—to enhance glycemic control. Primary indication is type 2 diabetes mellitus. Ipragliflozin was developed primarily by Astellas Pharma, and miglitol is an established agent marketed by several companies.

Brand names

SuglatGlysetDiastabolPlumarol

Other names

miglitolum